Q-omics provides the consensus-scored XPNPEP1 profile across patient tissues and cancer cell-line models. XPNPEP1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, XPNPEP1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, XPNPEP1 protein abundance shows 29,500 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, KIRC, and PDAC as cancer lineages where XPNPEP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for XPNPEP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes XPNPEP1 survival associations across molecular data types. XPNPEP1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible XPNPEP1 RNA expression–survival associations across cancer types. High XPNPEP1 expression shows unfavorable associations in ACC, LUAD, KICH, LIHC, BLCA and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for XPNPEP1 RNA expression.
This table summarizes XPNPEP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for XPNPEP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. XPNPEP1 shows higher tumor expression in KIRC, HNSC, LIHC, LUAD, KIRP and STAD. The KIRC box plot shows higher XPNPEP1 RNA expression in tumor versus normal tissue (log2 FC = +0.657, t-test p < 0.001).
This table shows molecular features associated with XPNPEP1 in patient tissues and cancer cell lines. In patient samples, XPNPEP1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, XPNPEP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
